Carna Biosciences Balance Sheet Health
Financial Health criteria checks 6/6
Carna Biosciences has a total shareholder equity of ¥2.7B and total debt of ¥58.4M, which brings its debt-to-equity ratio to 2.2%. Its total assets and total liabilities are ¥3.0B and ¥323.1M respectively.
Key information
2.2%
Debt to equity ratio
JP¥58.41m
Debt
| Interest coverage ratio | n/a |
| Cash | JP¥2.28b |
| Equity | JP¥2.65b |
| Total liabilities | JP¥323.13m |
| Total assets | JP¥2.98b |
Recent financial health updates
Health Check: How Prudently Does Carna Biosciences (TYO:4572) Use Debt?
Apr 11
Health Check: How Prudently Does Carna Biosciences (TYO:4572) Use Debt?
Dec 26
Recent updates
Carna Biosciences, Inc. (TSE:4572) Shares May Have Slumped 26% But Getting In Cheap Is Still Unlikely
Aug 06What Carna Biosciences, Inc.'s (TSE:4572) P/S Is Not Telling You
Apr 17Health Check: How Prudently Does Carna Biosciences (TYO:4572) Use Debt?
Apr 11How Much Did Carna Biosciences'(TYO:4572) Shareholders Earn From Share Price Movements Over The Last Five Years?
Feb 17Health Check: How Prudently Does Carna Biosciences (TYO:4572) Use Debt?
Dec 26Financial Position Analysis
Short Term Liabilities: 4572's short term assets (¥2.8B) exceed its short term liabilities (¥242.4M).
Long Term Liabilities: 4572's short term assets (¥2.8B) exceed its long term liabilities (¥80.7M).
Debt to Equity History and Analysis
Debt Level: 4572 has more cash than its total debt.
Reducing Debt: 4572's debt to equity ratio has reduced from 22.8% to 2.2% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 4572 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: 4572 has sufficient cash runway for 2.1 years if free cash flow continues to reduce at historical rates of 18.9% each year.